Amgen and AstraZeneca announce positive results from trial of psoriasis treatment
Amgen and AstraZeneca announce positive results from second pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis.
AstraZeneca presents new data from its growing inflammation and autoimmunity pipeline
AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from the company’s growing inflammation and autoimmunity portfolio at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts, 14-19 November 2014.
AstraZeneca PLC reports third quarter of growth
Pascal Soriot, AstraZeneca's Chief Executive Officer, commenting on the company's third quarter and nine months 2014 results, said: "I’m pleased to report our third consecutive quarter of revenue growth, driven by a strong contribution from our growth platforms."
AstraZeneca to divest Myalept to Aegerion
AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalised lipodystrophy.
AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology
Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers
AstraZeneca, Pharmacyclics and Janssen partner on immuno-oncology combination trials
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development, LLC today announced that they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton’s tyrosine kinase inhibitor, co-developed by Pharmacyclics and…
AstraZeneca completes strategic transaction with Almirall in respiratory disease
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company.
US FDA approves once-daily XIGDUO™ XR tablets for adults with Type 2 Diabetes
First US approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
AstraZeneca has today launched a programme aimed at tackling the burden of hypertension in Africa.
Lynparza™ (olaparib) receives positive CHMP opinion in the EU
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian,…
AstraZeneca strengthens partnership with the University of Cambridge
AstraZeneca, together with its global biologics research and development arm, MedImmune, today announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.
Positive results from Phase IIb benralizumab study in severe asthma published
AstraZeneca today announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell.
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response…
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in Euro label
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update* to the European label for IRESSA® (gefitinib).
MedImmune and Cancer Research UK establish joint lab to develop new biologic cancer medicines
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
FDA fast track designation for development of MEDI3902 for prevention of nosocomial pneumonia
AstraZeneca has announced that its global biologics research and development arm, MedImmune, has received fast track designation from the US Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa).
28-week results from AstraZeneca's DURATION-NEO-1 Phase III study
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes.
FDA approves MOVANTIK™ (naloxegol) tablets C-II
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
AstraZeneca & Redx Pharma: research collaboration targeting genetic drivers of tumour growth
AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival.
Data indicates Brilique™ has flexibility to be initiated pre-hospital/STEMI patients
AstraZeneca today announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILIQUE™/BRILINTA™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.
AstraZeneca announces partnership with Illumina
AstraZeneca today announced that it has entered into a collaboration with gene sequencing company, Illumina Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio.
AstraZeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration
AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announced a three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development
Positive top-line results from Phase III antibiotic programme
AstraZeneca today announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections.